CDC Surveillance Identifies Highly Divergent SARS-CoV-2 BA.3.2 Variant in U.S. Wastewater and International Traveler Samples

The CDC tracks the BA.3.2 COVID-19 variant across 25 states. While highly mutated for immune evasion, early data shows no increased severity or rapid dominance.

By: AXL Media

Published: Mar 26, 2026, 9:09 AM EDT

Source: Information for this report was sourced from CDC Morbidity and Mortality Weekly Report (MMWR)

Early Detection Through Multimodal Genomic Surveillance

The CDC’s latest Morbidity and Mortality Weekly Report (MMWR) emphasizes the critical role of advanced surveillance in identifying emerging viral threats before they trigger clinical surges. By integrating traveler-based genomic surveillance (TGS) with national wastewater monitoring, officials detected the BA.3.2 variant in the United States as early as June 2025. This proactive approach allowed researchers to map the variant's entry through international travel hubs—specifically a passenger arriving from the Netherlands—well before it was identified in domestic clinical settings. To date, the variant has been confirmed in 29 states and Puerto Rico, demonstrating a steady but non-explosive geographic expansion.

Genetic Divergence and Immune-Evasion Concerns

The BA.3.2 variant is notable for its significant genetic distance from previously dominant strains. It possesses approximately 70 to 75 substitutions and deletions in its spike protein relative to JN.1 and LP.8.1, the antigens used in the 2025–2026 COVID-19 vaccine formulations. These mutations are concentrated in the receptor-binding and N-terminal domains, areas of the virus that are primary targets for neutralizing antibodies. While this suggests a high potential for escaping immunity gained from prior infections or current vaccinations, the CDC notes that these laboratory-based concerns have not yet translated into a rapid displacement of other circulating variants in real-world settings.

Global Trends and Comparative Incidence

Since its initial identification in a pediatric sample in South Africa in November 2024, BA.3.2 has established a presence in diverse regions, including Mozambique, Germany, and Denmark. Global detections began to rise more sharply in September 2025, with European data showing the variant accounting for nearly 30% of sequences in countries like the Netherlands and Denmark during peak weeks. Despite this localized growth, overall SARS-CoV-2 infection rates in these regions have remained stable, suggesting that BA.3.2 may not possess the vastly increased transmissibility seen in previous "variant of concern" transitions.